It will compete with Eisai and Biogen's Leqembi, which the FDA approved last year ... Go deeper: Where the future of Alzheimer's drugs is heading Get more health news in your inbox with Axios ...

The Food and Drug Administration on ... Patients who carry two copies of the Alzheimer's risk gene, ApoE4, are more likely to ...

which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease ... drugs, but potentially life-threatening. It could also face a strong challenge if Eisai and Biogen get approval ...

The SEC concluded that Cassava Sciences falsified data in its Alzheimer’s clinical trials. Now the FDA needs to act, ...

The FDA confirmed ... with Alzheimer’s get their health coverage through Medicare. And private insurers have followed its lead by withholding coverage for Leqembi and a similar drug, Aduhelm ...

Alzheimer's is a brain disease that causes memory loss and thinking problems. It gets worse over time and is the most common ...

The two FDA-approved drugs have demonstrated in clinical trials the capability to slow cognitive decline by several months, The Washington Post reported Oct. 8.

Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after ...

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved treatment for early symptomatic Alzheimer’s disease.

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...